State of New Jersey Common Pension Fund D Has $11.81 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• The State of New Jersey Common Pension Fund D reduced its stake in Alnylam Pharmaceuticals by 7.9%, selling 3,758 shares and now holding a total of 43,745 shares worth approximately $11.8 million.
• Several institutional investors increased their stakes in Alnylam Pharmaceuticals, with overall institutional ownership at 92.97% of the company's stock.
• Analysts have upgraded the stock's price objectives, with Chardan Capital and Canaccord Genuity raising their targets to $400.00 and $415.00, respectively, reflecting a positive outlook for the company.

State of New Jersey Common Pension Fund D decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 43,745 shares of the biopharmaceutical company's stock after selling 3,758 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in Alnylam Pharmaceuticals were worth $11,812,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Capital World Investors raised its holdings in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock valued at $3,906,284,000 after purchasing an additional 92,101 shares in the last quarter. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Capital Research Global Investors raised its holdings in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 9.8% during the 1st quarter. American Century Companies Inc. now owns 1,760,435 shares of the biopharmaceutical company's stock worth $475,353,000 after acquiring an additional 156,411 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,979 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $3,163,371.33. Following the sale, the chief executive officer owned 56,221 shares of the company's stock, valued at $25,483,292.67. The trade was a 11.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Pushkal Garg sold 1,455 shares of the firm's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the transaction, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,269,508.61. The trade was a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 108,531 shares of company stock valued at $41,087,238. 1.20% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ALNY shares. Scotiabank raised their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research note on Friday, August 1st. Truist Financial began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, July 21st. They issued a "buy" rating and a $385.00 price objective for the company. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Needham & Company LLC lifted their target price on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Finally, UBS Group raised their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $405.33.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $0.03 during trading on Wednesday, reaching $458.31. 1,223,490 shares of the stock were exchanged, compared to its average volume of 959,532. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $466.31. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The company has a market capitalization of $60.08 billion, a P/E ratio of -185.55 and a beta of 0.25. The stock has a 50 day simple moving average of $351.27 and a 200-day simple moving average of $292.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773,689 billion during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.